ERBB2 and breast cancer: While the majority of tumors can be categorized as either HER2-positive or HER2-negative by IHC and in situ hybridization (ISH) techniques, which are regarded as the standard methods to assess HER2 status in BC, borderline tumors do account for up to 18% of BCs (18, 19) and present challenges for patient assessment and therapy choices.